EGFR and pancreatic neoplasm: Girgis et al. [16] first used epidermal growth factor receptor (EGFR)-targeted photoactivated multi-inhibitor liposomes (TPMILs) to remediate desmoplasia in a pancreatic ductal adenocarcinoma model containing patient-derived pancreatic cancer-associated fibroblasts.